tbuckley/cabot-search huggingface dataset:
1021. Development of a Syrian Hamster Animal Model To Study Replication Competent Adenovirus Vectors for Cancer Gene Therapy
Authors: Maria A. Thomas, Jacqueline F. Spencer, Karoly Toth, Marie C. LaRegina, Ann E. Tollefson, Baoling Ying, Mohan Kuppuswamy, Jennifer M. Meyer, Drew L. Lichenstein, Louis A. Zumstein, William S.M. Wold
Journal: Molecular Therapy (2005)

Replication-competent adenovirus vectors for cancer gene therapy are typically evaluated in immunodeficient nude or SCID mice bearing human xenograft tumors. However, the lack of an intact immune system in these animals lessens the relevance of these models to a clinical scenario. We have developed a novel Syrian hamster animal model for the study of oncolytic adenovirus vectors. Initially, we observed the expression of early and late adenovirus proteins in infected hamster cells at levels comparable to that seen in human A549 cells. Single step growth curves established that human adenovirus can replicate within and produce high virus yields in Syrian hamster cells. The yield per cell (burst size) was approximately 500 plaque forming units per cell, only one order of magnitude less than that obtained with A549 cells, one of the most permissive human cell lines known. We then confirmed that human adenovirus type 5 (Ad5) can replicate in the lungs of Syrian hamsters following endotracheal instillation. Three different Syrian hamster cancer cell lines were examined as subcutaneous tumor models in Syrian hamsters, and all three of these were found to form tumors following subcutaneous inoculation. Growth of these tumors was markedly suppressed following intratumoral injection with VRX-007, a replication-competent adenovirus vector developed in our laboratory, which overexpresses ADP (E3-11.6K). Furthermore, we found that VRX-007 replicates within tumors. Subcutaneous tumors formed by one of these hamster cell lines metastasized to the lungs and other organs. Intratumoral injection of VRX-007 suppressed the degree of metastasis. Histopathological analysis revealed areas of necrosis and degenerating tumor cells within tumors treated with VRX-007. These necrotic areas were located within viable areas of tumors, not in the central necrotic area, which most tumors contained. The necrotic regions were characterized as having a central core of debris which was primarily acellular, immediately surrounded by neutrophil infiltration and more peripherally surrounded by macrophages and fibroblasts. No such areas were observed within vehicle treated tumors. Our findings that Syrian hamster cells support productive adenovirus replication in vitro and that vectors developed in our laboratory show efficacy and replication in vivo demonstrate that the Syrian hamster can serve as a useful animal model to evaluate the safety and efficacy of oncolytic adenovirus vectors.
Protein metabolism in the intestinal stagnant loop syndrome.
Authors: E A Jones, A Craigie, A S Tavill, G Franglen, V M Rosenoer
Journal: Gut (1968)

The 14C carbonate method for the direct measure- ment of the synthesis rates of liver-produced plasma proteins (McFarlane, 1963) is a valuable new tecnnique for the study of protein metabolism in gastrointestinal diseases.It is the purpose of this communication to describe a study in which this technique has been applied to investigate the mechanism of the hypoproteinaemia and disordered protein metabolism which occur in the stagant loop syndrome. METHODSSamples of fasting jejunal contents were obtained using the capsule designed by Shiner, Waters, and Gray (1963) and the samples were cultured both aerobically and anaerobically.Viable bacterial counts were made using serial dilutions (Miles, Misra, and Irwin, 1938).Urinary indicans were measured by the method of Curzon and Walsh (1962).The distribution ratio and fractional and absolute catabolic rates of albumin were determined by the method of graphical analysis (Matthews, 1957) using human serum albumin (Behringwerke) which had been labelled with 1251 by a modification of the iodine mono- chloride technique (McFarlane, 1958).Plasma volumes, used in calculating the intravascular pools of the plasma proteins, were measured using 131I albumin.Concentrations of the plasma aminoacids were estimated using a Technicon amino-acid AutoAnalyzer.Absolute synthesis rates of albumin and fibrinogen were measured simultaneously by a modification of the 14C carbonate method (McFarlane, 1963).Urea pool sizes and urea synthesis rates were calculated from the curve of clearance from the plasma and the urinary excretion of a known mass of 13C urea (63.5 atoms% excess), administered intravenously (Craigie, Jones, Rosenoer, and Smallwood, 1967).The 13C atoms%7, excess of urea in plasma and urine samples were determined by mass spectrometry
Haloperidol and Propranolol in Combination
Authors: Thomas G. Burnakis
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The report by Alexander et al<sup>1</sup>of hypotension and cardiopulmonary arrest from concurrent haloperidol and propranolol therapy was interesting; however, I find difficulty in accepting part of their proposed mechanism. They state that α-receptor binding and relaxant effects of haloperidol, as well as "the relaxant effect on peripheral blood vessels by propranolol," could have led to the reported event. In actuality, propranolol is not felt to decrease peripheral resistance and may, because of β-blockade with unopposed α-stimulation, increase tone in these vessels.<sup>2</sup> Propranolol hydrochloride by itself in a 49-year-old man has caused a situation similar to the event described by these authors,<sup>3</sup>and has been associated with causing various, serious, cardiac arrhythmias.<sup>4</sup>In a similar manner, haloperidol by itself has been reported to cause multifocal premature ventricular contractions<sup>5</sup>that could also produce the clinical situation described by Alexander et al. Without further
Use of Alzheimer Disease Biomarkers
Authors: Ronald C. Petersen, John Q. Trojanowski
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Role for Vascular Endothelial Growth Factor in Acute and Resolving Lung Injury
Authors: David R. Thickett, Lynne Armstrong, Ann B. Millar
Journal: American Journal of Respiratory and Critical Care Medicine (2002)

We have previously reported, in patients with acute respiratory distress syndrome (ARDS), elevated plasma levels of vascular endothelial growth factor (VEGF) that became reduced in those who recovered. To examine the potential effect of VEGF on the epithelial side of the alveolar–capillary membrane, we compared VEGF levels in the epithelial lining fluid (ELF) of the same 40 patients with ARDS, and in 28 patients at risk of ARDS. We measured intrapulmonary VEGF levels in 23 patients on Days 1 and 4 after admission to the intensive therapy unit and related these levels to recovery. ELF from subjects with ARDS contained lower levels of VEGF than did ELF from at-risk subjects (1,076 and 7,674 pg/ml, respectively, p = 0.0004) and increased ELF levels at Day 4 were associated with recovery (p = 0.001). Alveolar macrophages from subjects with ARDS produced significantly less VEGF than those from at-risk subjects (6.3 and 13.0 pg/ml, respectively, p = 0.005). Similarly, alveolar neutrophils from subjects with ARDS produced significantly less VEGF than those at risk (13.9 and 31.5 pg/ml, respectively, p = 0.03). ELF VEGF levels inversely correlated with Lung Injury Score (p = 0.003). These studies suggest that VEGF in the alveolar space may reflect the development of, and recovery from, acute lung injury in a manner opposite to that in plasma.
Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families
Authors: Nobuyuki Hizawa, Linda R. Freidhoff, Eva Ehrlich, Yen-Feng Chiu b, David L. Duffy, Carsten Schou, Georgia M. Dunston, Terri H. Beaty, David G. Marsh, Kathleen C. Barnes, Shau-Ku Huang
Journal: Journal of Allergy and Clinical Immunology (1998)
Effects of sublingual nitroglycerin on resting pulmonary gas exchange and hemodynamics in man.
Authors: S Mookherjee, D Fuleihan, R A Warner, S Vardan, A I Obeid
Journal: Circulation (1978)

Simultaneous hemodynamic, ventilation and blood gas measurements were performed in 19 males during cardiac catheterization for evaluation of chest pain syndrome before and 3 to 5 min after 0.4 mg sublingual nitroglycerin. Pulmonary arterial pressures and total pulmonary vascular resistance fell (P less than 0.001 for both), and mean systemic arterial pressure decreased (P less than 0.05). However, peripheral vascular resistance, cardiac output, and mixed venous PO2 did not change. Total and tidal ventilation, PCO2, pH, and base excess remained unchanged. However, the arterial PO2 decreased from a mean of 80 +/- 3 (SEM) to 72 +/- 2 mm Hg (P less than 0.001) and mean venous admixture increased from 8.8 +/- 1% to 12.6 +/- 1.5% (P less than 0.001). The alveolar arterial PO2 difference increased (P less than 0.001) and the dead space tidal volume ratio rose (P less than 0.05). We conclude that the decrease in arterial PO2 following sublingual nitroglycerin is caused by redistribution of pulmonary blood flow with imbalance in ventilation-perfusion relationships or shunting.
Abstract B20: Immunotherapy as treatment for dogs with glioma.
Authors: Michelle Goulart, Elizabeth Pluhar, Brian Andersen, Charles Seiler, Matthew Hunt, Gerry O'Sullivan, Zoe Zhang, John Ohlfest
Journal: Cancer Research (2013)

Abstract Gliomas, the most invasive tumors of the brain, are a disparate group of oncological diseases for which there is currently no cure. Despite the use of combination therapy (surgery, radiation and chemotherapy) as the standard of care for patients, limited progress has been made in the control of the disease. Similar to that in humans, dogs develop spontaneous brain tumors that often carry a dismal prognosis regardless of therapeutic intervention. There is an obvious need for new therapies to treat dogs with brain tumors. Cancer immunotherapy, with the premise that tumor-reactive lymphocytes are able to infiltrate the brain to eradicate microscopic disease, is emerging as a promising strategy to treat glioma. To date, very little is known regarding canine glioma treatment outcome and there has been no reported randomized clinical trials examining the use of immunotherapy for treatment of glioma in dogs. A clinical trial using immunotherapy with autologous glioma cell lysate vaccines, combined with the TLR9 agonist CpG oligodeoxynucleotide to treat dogs with glioma, is underway in our laboratory. The objective of the treatment is to induce specific anti-tumor immunity in the brain and to prevent tumor recurrence. Our preliminary results have shown that vaccinated dogs exhibited extended survival when compared with historical controls. Based on western blot and flow cytometric analysis, this therapeutic approach induced tumor-reactive antibody responses with elevation of IgG antibody levels after vaccination. Thus, the examination of immune responses in therapeutic trials conducted in dogs with gliomas should greatly help predict outcomes of similar treatments in humans, and additionally provide an opportunity to accelerate the development of more efficient immunotherapeutic cancer vaccines for treatment of intracranial malignances. Citation Format: Michelle Goulart, Elizabeth Pluhar, Brian Andersen, Charles Seiler, Matthew Hunt, Gerry O'Sullivan, Zoe Zhang, John Ohlfest. Immunotherapy as treatment for dogs with glioma. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B20.
Neuropathy in Uremic Patients on Dialysis
Authors: H. Richard Tyler
Journal: New England Journal of Medicine (1975)

The paper in this issue of the Journal by Mitschke et al. concludes that transplantation was capable of reversing hearing loss in some of their dialyzed uremic patients. This result was not obtained in all their patients, suggesting that the specific nature of the abnormality was an important consideration in determining potential reversibility.According to the authors, four of these 10 patients had received an ototoxic drug. The fact that two patients with hereditary nephritis did not show improvement may suggest that they had a different type of otic abnormality from that noted in routine renal failure. A wide variety . . .
Conference on Mechanism of Protective Action of Kidney and Relation of Renoprival to Chronic Renal Hypertension
Authors: E. BRAUN-MENÉNDEZ
Journal: Circulation (1958)

This conference opened with an elaboration of the concept of the protective action of the normal kidney (Dr. Braun-Menéndez). After initiation of unilateral renal ischemia, the elevated blood pressure is reduced as the intact normal kidney hypertrophies to take over the work of the ischemic kidney. Removal of this intact kidney causes hypertension because the ischemic kidney cannot increase in size or function. As the protective action of the kidney is also lacking following bilateral nephrectomy, renoprival hypertension develops, providing the animals are kept alive long enough. The cause of renoprival hypertension remains obscure. Gross changes in salt and water metabolism do not have to be present (Dr. Grollman). The normal kidney may produce some material which lowers the blood pressure, or it may destroy or excrete a pressor substance (Dr. Handler). Excretory removal is not so likely as a cause, since the production of simple excretory failure by diverting urine back into the blood stream does not result in hypertension (Dr. Grollman). According to some participants, renoprival and chronic renal hypertension are not identical: Removal of a unilateral ischemic kidney causes the blood pressure to return to normal. This does not fit with the renoprival hypertension theory and is evidence that a pressor agent must be involved (Dr. Goldblatt). A further difference is that whereas antirenin lowers the blood pressure in chronic renal hypertension, it will not lower the blood pressure in renoprival hypertension (Dr. Helmer). Dr. Kolff, however cites reports, such as that of the failure of bilateral nephrectomy to cure renal hypertension, which favor the view that the mechanism of production is the same in both forms of hypertension. Both groups finally agreed that some cases of renal and of renoprival hypertension could not be explained by assuming a single mechanism of action.
Fusobacterium necrophorum Septicemia Following Oropharyngeal Infection
Authors: Steven M. Seidenfeld, William L. Sutker, James P. Luby
Journal: JAMA (1982)

<i>Fusobacterium necrophorum</i>septicemia developed in five patients after an oropharyngeal infection. Four patients had sore throat or neck pain, and two had findings of jugular vein septic thrombophlebitis. Metastatic abscesses, including embolic pneumonia, empyema, septic arthritis, and osteomyelitis, also occurred. Four patients recovered and one died. Proper treatment requires recognition of the oropharyngeal source of the septicemia and its differentiation from endocarditis. Antibiotic therapy should be prolonged, and metastatic abscesses drained. (<i>JAMA</i>1982;248:1348-1350)
Toxicity of Mediastinal Irrigation With Bacitracin
Authors: Eric L. Westerman
Journal: JAMA (1983)

<h3>To the Editor.—</h3> It is well recognized that topical application of antibiotics can result in systemic absorption. We report a case in which mediastinal irrigation with bacitracin solution resulted in a potentially toxic serum level of the drug. <h3>Report of a Case.—</h3> A 70-year-old man with severe chronic obstructive lung disease underwent a coronary artery bypass. The postoperative course was complicated by respiratory difficulties, and, on the 14th postoperative day, sternal dehiscence occurred. He was taken back to surgery, where sternal closure was performed. Because of the possibility of mediastinitis, three irrigation tubes were inserted with three sump drains. Through each irrigation tube, normal saline containing bacitracin, 50,000 units/L, was infused at 100 mL/hr for a total of three days. On the second day, a serum bacitracin level was measured at 10.7 units/mL. During this period, the serum urea nitrogen level rose from 16 mg/dL to 30 mg/dL. The serum
Efficacy of an Evidence-Based Clinical Decision Support in Primary Care Practices
Authors: Thomas G. McGinn, Lauren McCullagh, Joseph Kannry, Megan Knaus, Anastasia Sofianou, Juan P. Wisnivesky, Devin M. Mann
Journal: JAMA Internal Medicine (2013)

There is consensus that incorporating clinical decision support into electronic health records will improve quality of care, contain costs, and reduce overtreatment, but this potential has yet to be demonstrated in clinical trials.To assess the influence of a customized evidence-based clinical decision support tool on the management of respiratory tract infections and on the effectiveness of integrating evidence at the point of care.In a randomized clinical trial, we implemented 2 well-validated integrated clinical prediction rules, namely, the Walsh rule for streptococcal pharyngitis and the Heckerling rule for pneumonia. INTERVENTIONS AND MAIN OUTCOMES AND MEASURES: The intervention group had access to the integrated clinical prediction rule tool and chose whether to complete risk score calculators, order medications, and generate progress notes to assist with complex decision making at the point of care.The intervention group completed the integrated clinical prediction rule tool in 57.5% of visits. Providers in the intervention group were significantly less likely to order antibiotics than the control group (age-adjusted relative risk, 0.74; 95% CI, 0.60-0.92). The absolute risk of the intervention was 9.2%, and the number needed to treat was 10.8. The intervention group was significantly less likely to order rapid streptococcal tests compared with the control group (relative risk, 0.75; 95% CI, 0.58-0.97; P= .03).The integrated clinical prediction rule process for integrating complex evidence-based clinical decision report tools is of relevant importance for national initiatives, such as Meaningful Use. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01386047.
Site specific systemic delivery of rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model
Authors: Nicholas N. Kipshidze, Ahmadian Yazdi, Fermin Tio, Rufus Seaborn, Tom Porter, Milena G. Adamian, Feng Xie, George Dangas, Martin B. Leon, Jeffrey W. Moses, Patrick Iversen
Journal: Journal of the American College of Cardiology (2003)
Gene for Progressive Familial Heart Block Type I Maps to Chromosome 19q13
Authors: Paul A. Brink, Alet Ferreira, Johanna C. Moolman, Hettie W. Weymar, Pieter-Luttig van der Merwe, Valerie A. Corfield
Journal: Circulation (1995)

Progressive familial heart block type I (PF-HBI) is a dominantly inherited cardiac bundle-branch conduction disorder that has been traced through nine generations of a large South African kindred. Similar conduction disorders have been reported elsewhere; however, the cause of these diseases is unknown. The aim of the present study was to determine by linkage analysis the approximate chromosomal position of the gene causing PFHBI, thereby allowing family-based diagnosis and the development of positional cloning strategies to identify the causative gene.Eighty-six members of three pedigrees, 39 members of which were affected with PFHBI, were genotyped at four linked polymorphic marker loci mapped to chromosome 19, bands q13.2-q13.3 (chromosome 19q13.2-13.3). Maximum two-point logarithm of the odds scores (which represent the logarithm of the odds ratio of detecting linkage versus nonlinkage) generated were 6.49 (theta = 0) for the kallikrein locus, 5.72 (theta = 0.01) for the myotonic dystrophy locus, 3.44 (theta = 0) for the creatine kinase muscle-type locus and 4.51 (theta = 0.10) for the apolipoprotein C2 locus. The maximum multipoint logarithm of the odds score was 11.6, with the 90% support interval positioning the PFHBI locus within a 10 cM distance centering on the kallikrein 1 locus.The gene for PFHBI maps to an area of approximately 10 cM on chromosome 19q13.2-13.3. There are several candidate genes in this interval; although a recombination event ruled out the myotonic dystrophy locus from direct involvement with PFHBI, the proximity of these two loci may be relevant to the observed cardiac abnormalities of myotonic dystrophy. The results provide a means of DNA-based diagnosis in the families studied and a foundation for cloning studies to identify the causative gene.
Erratum to: “Prevalence of Erectile Dysfunction in France: Results of an Epidemiological Survey of a Representative Sample of 1004 Men” [Eur. Urol. 42 (2002) 382–389]
Authors: Francois Giuliano, Marie Chevret-Measson, Anne Tsatsaris, Caroline Reitz, Michel Murino, Patrick Thonneau
Journal: European Urology (2002)
Using Computers Usefully
Authors: B. Benjamin
Journal: BMJ (1970)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Using Computers Usefully Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The primary angioplasty in myocardial infarction (PAMI) trial
Authors: Gregg W. Stone, Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum, James O'Keefe, Geoffrey O. Hartzler, Paul Overlie, Bryan Donohue, Noah Chelliah, Gerald C. Timmis, Ronald Vlietstra, Michelle Strzelecki, Sylvia Puchrowicz-Ochocki, William W. O'Neill
Journal: Journal of the American College of Cardiology (1995)
768-1 Coronary Lesion Histology in Stable, Unstable and Evolving Angina Pectoris
Authors: James M. Wilson, Pavel Capek, H.A. McAllister, William K. Vaughn, James J. Ferguson, Fred J. Clubb, L. Maximilian Buja, James T. Willerson
Journal: Journal of the American College of Cardiology (1995)
High hepatic glutathione stores alleviate Fas-induced apoptosis in mice
Authors: Sophie Cazanave, Alain Berson, Delphine Haouzi, Nathalie Vadrot, Daniel Fau, Alain Grodet, Philippe Lettéron, Gérard Feldmann, Jamel El-Benna, Bernard Fromenty, Marie-Anne Robin, Dominique Pessayre
Journal: Journal of Hepatology (2006)